Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from September 3, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 2, 2025.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted
$43.92 Published $60.61 Target $36.31 Window close $65.30 Peak
$42.50 – $44.00Entry zone — fair-value band
$43.92Published — price the day we called it
$60.61Target — the price the thesis aimed for
$65.30Peak — highest point inside the window, not a realized return
$36.31Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 42 days.

Peak price
$65.30
peak on October 15, 2025 — not a realized return
Peak gain
+48.7%
peak, from the publication price
Window close
$36.31
end-of-window price, context only
Days to target
42
Window
September 3, 2025 – December 2, 2025

The thesis — published September 3, 2025

Predicted growth
+38%
over the measurement window
Target price
$60.61
the price the thesis aimed for
Entry zone
$42.50 – $44.00
the fair-value band we waited for
Price at publication
$43.92
published September 3, 2025
Confidence
86%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

The stock looks beaten down but interest from buyers is still solid, setting up a likely 1-3 month bounce. The business now serves over 2.4 million subscribers and keeps adding new wellness offerings. A legal review tied to Wegovy access is a known worry. If the price pushes back above its recent average and momentum improves, selling pressure may ease and the stock could snap back quickly.

Primary drivers

  • Price looks overly beaten down while buyer interest remains steady
  • Large and growing subscriber base plus new wellness offerings
  • Stronger trading activity often precedes short-term rebounds
  • Legal probe adds uncertainty that could affect investor mood

How it played out

HIMS: target reached in 42 days

Lyra published HIMS at $43.92 on 2025-09-03 with a short-term bounce thesis. The expected growth was 38%, with a target of $60.61. The thesis pointed to a beaten-down setup, steady buyer interest, over 2.4 million subscribers, new wellness offerings, stronger trading activity, and legal uncertainty tied to Wegovy access.

Inside the window, HIMS reached a peak of $65.30 on 2025-10-15, a 48.7% gain. It reached the target in 42 days. By 2025-12-02, it ended at $36.31. The thesis played out on the target, even though the stock later fell back below the publication price.

What happened during the window

On October 15, 2025, The Wall Street Journal reported that Hims & Hers had begun offering menopause and perimenopause care. The same day, Investors.com reported the launch and said the shares rose after the announcement.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals